Sign in

NCT07441486Not yet recruitingPhase 2

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Source: ClinicalTrials.gov · Last updated 2 Mar 2026

Brief summary (registry, in English)

Objective: To explore the curative effect and safty of Changchun Ruibin metronomic chemotherapy combined with endistat in the treatment of HR positive HER2 negative advanced breast carcinoma.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
50 (estimated)
First submitted
11 Jun 2025
Start date
1 Apr 2026
Primary completion date
10 Apr 2026
Lead sponsor
Tianjin Medical University Cancer Institute and Hospital
NCT number
NCT07441486

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 50
  • From 1 Apr 2026 to the primary completion date, 10 Apr 2026
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Only participants who meet all of the following eligibility criteria will be eligible for this trial:
  • Age ≥ 18 years;
  • Patients with advanced breast carcinoma confirmed by histopathological and / or cytological examination;
  • HER2-negative breast carcinoma with confirmed HR positive primary and / or metastatic lesions;
  • At least one evaluable tumor lesion (according to RECIST1.1);
  • Prior 2-4 lines of therapy, which must include one endocrine therapy with CDK4 / 6 inhibitors, one chemotherapy with paclitaxel.
  • Previous 1L of ADC drug therapy is acceptable.
  • Complete clinical data on important research indicators;
  • The Eastern Oncology Assistance Group (ECOG) physical fitness status score was 0-2;
  • Life expectancy \> 6 months.

Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.